Table 5.
Association of efficacy with treatment strategies in RET fusion positive NSCLC
| Agent | ORR (%) | mPFS (mo) | mOS (mo) | Common Gr 3 or 4 AEs | Refs |
|---|---|---|---|---|---|
| Selpercatinib (first line) | 85 | NR | Hypertension, elevated AST, ALT, | [27] | |
| Pralsetinib (first line) | 73 | NR | Anemia, hypertension, Neutropenia, | [32] | |
| Vandetanib | 18 | 4.5 | 11.6 | Hypertension, diarrhea, rash, dry skin, QT prolongation | [41] |
| Cabozantinib | 28 | 5.5 | 9.9 | Elevated lipase, ALT, AST, thrombocytopenia, hypophosphatemia | [42] |
| CPI (Nivolumab or Pembrolizumab) | 12.7 | 3.4 (95% CI 1.7–6.2) | 18.4 (95% CI 7.0–NR) | NA | [8] |
| Platinum-Pemetrexed (first line) | 50 | 9.2 | 26.4 | NA | [37] |
CPI, Checkpoint inhibitor; AST, Aspartate aminotransferase; ALT, Alanine aminotransferase; NA, Not available (these were retrospective studies focused on efficacy)